Changzhou Boyi Biotechnology
Health · China
Raw materials and solutions for in-vitro diagnostics MoreLess
Changzhou Boyi Biotechnology Co., Ltd. is a technology-focused enterprise centered on the in-vitro diagnostic industry. The company originated in 2013 as Changzhou Tiandi Renhe Biotechnology Co., Ltd., founded by a group of experts in polymer materials, proteomics, and molecular biology to focus on the purification of biological macromolecules. The Boyi Bio Group itself was established in 2022 and now owns brands such as Tiandi Renhe, Boyi Bio, and ACE. The chairman and general manager is Fang Li.
Boyi Biotechnology provides key raw materials and integrated solutions for biomedical clients. The business is structured around three main sectors: purification of biological macromolecules, core raw materials for in-vitro diagnostic reagents, and life science research reagents. The company's product lines include diagnostic microspheres, testing raw materials, and quality control products. Specifically, they produce a range of chromatography resins (gel filtration, affinity, ion exchange, hydrophobic interaction), magnetic beads, and various biological reagents and instruments under its ACE brand. These products are used in applications such as recombinant proteins, vaccines, antibodies, gene therapy, and cell therapy.
The company has made significant investments in its infrastructure, with a total project investment of RMB 300 million for a 45,000-square-meter facility in Changzhou's Xitaihu Industrial Park, which includes R&D, office, and production buildings with 10 automated production lines expected to be operational in the second half of 2024. Boyi Biotechnology has received recognition as a National High-tech Enterprise in 2019 and was named a provincial "Potential Unicorn" and "Gazelle" enterprise. As of early 2024, the company holds 6 authorized invention patents and 62 utility model patents. In July 2023, it successfully obtained ISO 13485:2016 certification for its medical device quality management system.
Keywords: in-vitro diagnostics, biological raw materials, diagnostic microspheres, chromatography resins, protein purification, life sciences, affinity chromatography, ion exchange, molecular sieves, biomedical solutions, antibody purification, gene therapy, cell therapy, biological reagents, quality control products, biopharmaceuticals, macromolecule purification, medical device manufacturing, polymer material science, clinical laboratory medicine
Company overview
Changzhou Boyi Biotechnology company information
The essential company record, classifications and operating signals in one place.
- Status
- Operational
- Founded
- —
- Headquarters
- China
- Employees
- —
- Open positions
- None listed
- Dealroom signal
- 11.7
Valuation & funding
Changzhou Boyi Biotechnology funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES A✓Equity / VC | May 2023 | $14M | $55M | Bangsheng Capital · Jinyu Bogor | ↗ |
Growth signals
Changzhou Boyi Biotechnology website traffic
Latest recorded traffic for Changzhou Boyi Biotechnology is 560 monthly website visits, up 833.3% over the last three months.
Comparisons
Changzhou Boyi Biotechnology compared with similar companies
Dealroom’s weighted taxonomy model identifies the closest operating peers. Company identity and context stay open; selected comparison metrics preview what is available in the platform.
Talent graph
Changzhou Boyi Biotechnology's talent
Source: Dealroom Talent Intelligence.
Investors
2 investors on Changzhou Boyi Biotechnology's cap table
Sourced from Dealroom's funding and investor records.

Global footprint
Where Changzhou Boyi Biotechnology has talent and traffic
In the news
Latest news about Changzhou Boyi Biotechnology
Recent press, funding announcements, and product moves mentioning Changzhou Boyi Biotechnology — open to read from the original sources.
Market sentiment
What the market is saying about Changzhou Boyi Biotechnology
An AI-synthesized read of the highest-engagement posts about Changzhou Boyi Biotechnology on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Changzhou Boyi Biotechnology’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.






